FT-017

FT-017 is an investigational **rAAV gene therapy** being developed by Fronterra for **hypertrophic cardiomyopathy**. Publicly available pipeline information identifies FT-017 as a **preclinical** cardiovascular program and indicates that the modality is recombinant adeno-associated virus gene therapy, but the **specific transgene, molecular target, and detailed mechanism have not been publicly disclosed**. Based on the disclosed modality, FT-017 is intended to deliver a therapeutic genetic payload to cardiac tissue to address the underlying biology of HCM rather than provide purely symptomatic treatment.

Other names

FT-017 Fronterra rAAV gene therapyFT017 Fronterra rAAV gene therapyFT 017 Fronterra rAAV gene therapy